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The isolation of mammalian cell lines capable of high-
yield expression of recombinant antibodies is typically
performed by screening multiple individual clones by
limiting dilution techniques. A number of experimental
strategies have recently been devised to identify high-
expressing clones, but protocols are often difficult to
implement, time consuming, costly and limited in terms
of number of clones which can be screened. In this
article, we describe new vectors for the expression of
recombinant antibodies in IgG format and in other
formats, based on the single-chain Fv module, as well as
a high-throughput screening procedure, based on the
direct staining of antibodies transiting the membrane of a
stably transfected cell, followed by preparative sorting
using a high-speed cell sorter. This procedure allows, in
one step, to deposit single cells into individual wells of a
96-well microtiter plate (thus facilitating cloning) and to
preferentially recover those rare cell populations which
express dramatically higher levels of recombinant anti-
body. Using cell cultures followed by affinity purification
techniques, we could confirm that the new vectors
and the new screening procedure reliably yield high-
expression clones and homogenous protein preparations.
We expect that these techniques should find broad
applicability for both academic and industrial antibody
engineering research.
Keywords: CHO/fluorescence activated cell sorting/
recombinant protein production/selection
Introduction
Monoclonal antibodies represent the fastest growing class of
pharmaceutical biotechnology products (Walsh, 2005), with
sales in 2007 which exceeded 20 billion US dollars (Pavlou
and Belsey, 2005). At present, antibody biopharmaceuticals
typically consist of antibodies in IgG format (Carter, 2006).
However, antibody derivatives [e.g. radiolabeled antibodies
(Milenic et al., 2004), antibody-cytokine fusion proteins
(Reisfeld et al., 1997; Neri and Bicknell, 2005) and antibody-
drug conjugates (Kovtun and Goldmacher, 2007; Carter and
Senter, 2008)] are increasingly being used in pharmaceutical
development programs. The facile cloning and high-titer
expression of monoclonal antibodies and their derivatives,
thus, represent a topic of considerable interest for the develop-
ment and use of this important class of biopharmaceuticals.
While the expression of full immunoglobulins in bacteria
(Simmons et al., 2002; Mazor et al., 2007) and in yeast (Li
et al., 2006) has recently been reported, antibodies in IgG
format are typically over-expressed in mammalian cells for
pharmaceutical applications (Wurm, 2004). In most cases, the
heavy and light chains of an IgG molecule are encoded in
different plasmids which are co-transfected into recipient
Chinese hamster ovary (CHO) cells, and a variety of different
vectors have been designed for this purpose (Persic et al.,
1997; Borsi et al., 2002; Li et al., 2007). However, co-
transfection procedures often lead to relatively low yields of
high-expressing clones, and typically several thousand stably
transfected clones have to be analyzed using single-cell
dilution procedures, in order to identify those rare clones
which produce large antibody quantities in a stable fashion. A
number of procedures have been proposed which may lead to
high antibody-titers and to a higher frequency of transfectants
with good expression properties. These include the use of suit-
able introns in the promoter region of expression vectors
(Chapman et al., 1991) and the use of survival genes which
permit the selection of high expressing clones in selective
media. Lonza Biologics has developed a mammalian
expression system that makes use of selection via glutamine
(GS) metabolism. For cells which do not express sufficient GS
to survive without adding glutamine, a transfected GS gene
can function as a selectable marker by permitting growth in
glutamine-free medium (Bebbington et al., 1992). Another
expression system uses the dihydrofolate reductase gene as a
survival gene (Alt et al., 1978). Furthermore, certain sequences
flanking the antibody genes (termed ‘Matrix Attachement
Regions’) have been reported to bind isolated nuclear scaffolds
or nuclear matrices in vivo with high affinity and to reduce the
effects of heterochromatin (Zahn-Zabal et al., 2001; Wurm,
2004; Girod et al., 2005) thus leading to over-expression of the
corresponding transfected gene. Transfection techniques have
also been reported to substantially affect expression yields
(Baldi et al., 2007), and there is a growing interest in the defi-
nition of insertion sites as well as number of insertion events
(Chenuet et al., 2008). Researchers are even considering
antibody-production processes which rely on the transient
transfection of rapidly dividing CHO cells using polyethyleni-
mine or calcium phosphate and disposable plastic shakers
(Derouazi et al., 2004; Haldankar et al., 2006).
In addition to the above-mentioned developments in
expression vectors and host cells, pharmaceutical companies
and research laboratories are currently focusing on the
implementation of advanced screening methods, which may
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allow analysis of several thousand transfected cells, for
example, by growing colonies in semi-solid agar with fluor-
escent detection of the halo of secreted antibodies in the
immediate cell proximity (Davis et al., 1982; Mann, 2007) or
by multiple rounds of fluorescence-activated cell sorting pro-
cedures (Ernst et al., 1998; Brezinsky et al., 2003), some-
times using green fluorescent protein as an indirect reporter
of transgene expression (Meng et al., 2000).
In this article, we describe a new set of vectors for the
mammalian expression of antibodies in IgG format or as
scFv-based fusion proteins. Furthermore, we describe for the
first time, to the best of our knowledge, a fluorescence-based
screening methodology which does not make use of semi-
solid agar but, instead, features only a single round of FACS
sorting in sterile conditions. The new procedure allows in
one step to separate a mixture of cells into individual clones,
while at the same time selecting high-expressing clones from
a pool of stably transfected cells. We exemplified our pro-
cedure using the clinical-stage human monoclonal antibody
L19 (Pini et al., 1998), which is specific to the alternatively
spliced EDB domain of fibronectin, a marker of angiogenesis
(Zardi et al., 1987; Neri and Bicknell, 2005; Kaspar et al.,
2006; Schliemann and Neri, 2007). We expressed the L19
antibody both in IgG format and in SIP format (Borsi et al.,
2002; Berndorff et al., 2005; Tijink et al., 2006) and con-
firmed that our FACS-based procedure reliably leads to a
substantially higher frequency of over-expressing cell lines,
which grow in suspension, are stable over multiple passages
and which yield well-behaved protein preparations using
GMP-compatible downstream processing procedures.
Results
Figure 1 depicts a schematic representation of the FACS-based
selection procedure used for the identification and cloning of
high-producing cells, out of a population of stably transfected
CHO cells. We reasoned that, during antibody secretion, a
non-negligible quantity of antibody molecules could still
remain associated to the cell membrane, thus allowing detec-
tion using suitable fluorescently labeled affinity reagents (e.g.
rabbit polyclonal anti-human IgG antibodies). Unlike the
semi-solid agar method, which requires the use of a dedicated
imaging and picking instrument and the preparation of agar
plates (Mann, 2007), we preferred to use preparative FACS
sorting device, as these instruments are commonly available at
most biomedical research institutions.
Figure 2 presents a schematic representation of the new
vectors developed for stable antibody over-expression, and of
the corresponding antibody molecules. Plasmid pBL1 is a
derivative of pcDNA3.1, which contains a SIP secretion
sequence (Li et al., 1997) in frame with the scFv(L19)
(Huston et al., 1988) fused to the 1CH4 domain of human
IgE. We have used similar strategies for the cloning,
expression and selection of a variety of different scFv-based
fusion proteins in the lab, including immunocytokines which
would otherwise typically exhibit expression yields at levels
below mg/liter (R.S., E.T., M.K., D.N., unpublished result).
We chose to use pcDNA3.1 as basic vector for protein
expression and to avoid gene amplification strategies,
because of the well-documented long-term stability of such
expression strategies (Jun et al., 2006). Similarly, for IgG
expression, we developed two pcDNA3.1-derived plasmids
(pKZ1 and pKZ2), which direct the expression of heavy and
light chains of the IgG(L19) molecule and which contain
different antibiotic resistance genes (hygromycin for the
heavy chain and neomycin for the light chain).
Figure 3A shows a representative FACS profile obtained
after electroporation of CHO-S cells with the vector pBL1,
coding for SIP(L19). While the FACS profile was shifted
towards higher fluorescence values compared to a non-
transfected cell population, only a minor fraction of trans-
fected cells exhibited a substantially higher fluorescence
signal. This population was separated from the main body of
transfected cells by FACS sorting, and a representative
number of single cells were generated by preparative sorting
procedures, then growing the individual clones in microtiter
plates. Figure 3B shows that 19/24 FACS sorted cells yielded
ELISA values greater than 1, while only 3/24 high expressors
were identified in the negatively sorted population. In full
analogy, preparative FACS sorting of individual cells doubly
transfected for IgG expression resulted in a higher frequency
of over-expressing clones (Fig. 3C and D).
Clones generated by preparative FACS sorting, as described
in Fig. 3, could be amplified without problems of sterility or
of loss of expression up to the 1000 ml volume, growing cells
in suspension and allowing the production of banks of cryo-
tubes. For both SIP(L19) and IgG(L19), these cell banks could
be used for antibody production in larger scale, using either
roller bottles, shaker flasks or fermenters, yielding hom-
ogenous protein preparations after purification on Protein-A
resin (Fig. 4A and B). Homogeneity of SIP(L19) and
IgG(L19) preparation was confirmed by gel-filtration analysis
Fig. 1. Schematic representation of the FACS-based selection procedure.
Antibodies (depicted in dark grey) secreted from the cell still remain
associated to the cell membrane and can be detected with a fluorescently
labeled reagent (in black). Fully secreted antibodies (in light grey) are
washed away during staining procedure. A cell with a high secretion rate
(i.e. many antibodies still attached to the membrane) gives a high FITC
signal in the FACS profile and is selected as a high expressing clone.
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(Fig. 4C and D). Furthermore, SIP(L19), a non-glycosylated
recombinant antibody, was shown to be homogenous using
both MALDI-TOF analysis and two-dimensional polyacryl-
amide gel electrophoresis (Fig. 4E and F).
Highly fluorescent stably transfected IgG clones, after
sorting, typically express .10 mg/l in T-flasks using
PowerCHO medium in unoptimized conditions, while the
same vectors exhibited yields of 1 mg/l in the same con-
ditions upon isolation by limiting dilution (Borsi et al.,
2002). Similarly, highly fluorescent SIP(L19) clones after
FACS sorting exhibited yields in T-flasks in unoptimized
conditions .20 mg/l.
Discussion
Using conventional single-cell dilution methodologies,
IgG(L19) and SIP(L19) had previously been expressed at the
low milligram per liter level (Borsi et al., 2002). The new
preparative FACS sorting procedure described in this article
led to populations of clones which expressed at least 10
times more antibody compared to clones generated by
random single-cell dilution. Preliminary fermentation exper-
iments in 30 l fermenters indicate the expression yields for
both SIP(L19) and IgG(L19) can be substantially improved
through judicious choice of growth medium, fermentation
parameters and media supplement. Based on our experience
with various formats of the L19 antibody and of other
clinical-stage antibodies developed in our lab [e.g. the F16
antibody specific to the alternatively spliced domain A1 of
tenascin-C; (Brack et al., 2006), and the F8 antibody specific
to the alternatively spliced EDA domain of fibronectin (Villa
et al., 2008)], we believe that the vectors and the preparative
FACS sorting procedures described in this article may
be of general utility for a variety of different laboratories
Fig. 2. (A) Schematic representation of vector pBL1 directing the expression of SIP(L19). Relevant features of this plasmid are indicated, together with DNA
and amino acid sequences, including the sequences of the linker connecting VH and VL in the scFv portion of the molecule (Huston et al., 1988) and of the
linker connecting the scFv fragment with the C-terminal eCH4 domain of human IgE (Borsi et al., 2002). (B) Vectors pKZ1 and pKZ2, which direct the
expression of the heavy and light chains of IgG(L19). Cloning sites and relevant features of the vector are indicated. SS, secretion sequence.
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active in the development of antibody-based therapeutics.
Protein-A-based downstream purification procedures were
facilitated by the fact that all antibodies isolated in our lab-
oratories derived from human antibody libraries based on the
DP47 heavy chain germline family (Pini et al., 1998; Silacci
et al., 2005), which has long been known to confer protein-A
binding also to scFv-based antibody formats (Hoogenboom
and Winter, 1992). Furthermore, we have observed that a
range of fluorescently labeled detection reagents can be used
for the preparative FACS-sorting step, e.g. fluorescently
labeled antigen or fluorescently labeled protein-A.
Materials and methods
Plasmids and transfections
Vector pBL1, directing the expression of the recombinant anti-
body SIP(L19) has previously been described (Borsi et al.,
2002). Briefly, the SIP format consists of L19(scFv) and the
1CH4 domain of the human IgE secretory isoform IgE-S2,
which allows dimerization. This plasmid was used to transfect
CHO-S cells (Gibco/Invitrogen, Basel, Switzerland) using
Amaxa Nucleofector (Amaxa AG, Cologne, Germany) follow-
ing the manufacturer’s protocol. Transfectomas were grown
in RPMI supplemented with 10% FCS and selected using
500 mg/ml of Geneticin (G418, Calbiochem, San Diego, CA,
USA).
The heavy and light chain gene for the complete IgG(L19)
were amplified from the constructs pcDNA3-L19IgG1 and
pCMV2D-L19-k (Borsi et al., 2002) by polymerase chain
reaction using High Fidelity Polymerase (Roche) according
to the manufacturer’s recommendations. For the complete L19
light chain primers 1_BW_SEC (CCCAAGCTTGTCGACCA
TGGGCTGGAGCCT GAT) and 14_FW_hCk (GGCCTCGA
GCTAACACTCTCCCCTGTTGAAGCTC TTT), containing
HindIII and XhoI restriction sites, respectively, were used.
After digestion with HindIII and XhoI, the amplification
product was inserted in the vector pcDNA3.1 containing a
neomycin resistance gene, to obtain the construct pKZ2.
For subcloning the complete heavy chain in the vector
pcDNA3.1 containing a hygromycin resistance gene, primers
1_BW_SEC (CCCAAGCTTGTCGACCA TGGGCTGGAG
CCTGAT) and 6_FW_hCG1 (TTTTCCTTTTGCGGCCG
CGCTCGGTACCCGGGGAGC) containing the HindIII and
NotI restriction sites, respectively, were used. The amplifica-
tion product was digested and inserted HindII/NotI in
pcDNA3.1, yielding vector pKZ1.
Equimolar amounts of these constructs were used to
cotransfect CHO-S cells as described above. Transfectomas
were selected using 500 mg/ml of Geneticin (G418,
Calbiochem, San Diego, CA, USA) and 25 mg/ml hygromy-
cin B (Invitrogen, Carlsbad, CA, USA).
After 14 days of selection in RPMI medium supplemented
with 10% FCS and selective antibiotics, cells were brought
into suspension, and cultured in PowerCHO-CD 2 (Lonza,
Vervier, Belgium).
Staining of recombinant CHO for secreted product
and fluorescent-activated cell sorting
Cells were cultured in suspension in T75 cell culture flasks to
a density of 5  105 cells/ml. For collection of the cells, the
suspension was centrifuged 5 min at 1100 rpm, the cells were
then resuspended in PBS to a final concentration of about 5 
106cells/ml. In general, 5  105 to 1  106 cells were labeled
for the sorting procedure. To stain recombinant CHO for
secreted product, the following antibodies were used: for
the detection of SIP(L19) a rabbit anti-human IgE (Dako,
Fig. 3. Key features of the FACS sorting procedure and ELISA results (A). Histogram of fluorescent-activated cell sort for SIP(L19) transfected CHO cells.
As negative control untransfected CHO cells were used. Horizontal bars indicate the high-fluorescence and low-fluorescence cell populations used for the
single cell recovery steps, using FACS in the preparative mode (B). Expression levels detected by ELISA of clones selected from high-fluorescent and
low-fluorescent populations (C and D).
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Glostrup, Denmark), diluted according to the manufacturer’s
recommendations, and in the case of the IgG(L19) a rabbit
anti-human IgG (Dako, Glostrup, Denmark). The samples
were then incubated with the antibodies at room temperature
for 1 h. After washing with PBS, the secondary antibody, an
Alexa Flourw 488 conjugated anti-rabbit IgG (Molecular
Probes, Eugene, OR, USA), was incubated at room tempera-
ture for 1 h in the dark. Next, cells were washed twice with
PBS and transferred to a FACS tube and kept on ice. Twenty
minutes before sorting, 7-aminoactinomycin (7-AAD) was
added in a 1:1000 dilution to stain dead cells. Analytical flow
cytometry scans were performed on the FACSCanto (Becton
Dickinson, Basel, Switzerland). Data were analyzed with
Flowjo software (Treestar, Ashland, TN, USA).
FACS was performed using a BD FACSAria (Becton
Dickinson, Basel, Switzerland) equipped with FACSDiva
software, an argon laser emitting at 488 nm and an automatic
cell deposit unit for plate sorting. The 7-AAD staining was
used to identify dead (or dying cells) and PerCP-Cy5.5 emis-
sion was detected using a 695/40 bandpass filter. The FITC
emission was detected using 530/30 bandpass filter. Dead
cells were excluded in a FSC vs. PerCP-Cy5.5 dot blot.
Fluorescently labeled cells positive for FITC and negative
for 7-AAD were single cell deposited using FACS into
96-well flat bottom ‘tissue culture treated’ microplates (Nunc,
Roskilde, Denmark) containing 200 ml RPMI supplemented
with 10% FCS, G418 and hygromycin B. Clones were incu-
bated at 378C and 5% carbon dioxide in a humidified incuba-
tor for 10–14 days.
ELISA of supernatants
ELISA experiments on the conditioned culture media were per-
formed according to Carnemolla et al. (Carnemolla et al.,
1996). To detect different clones expressing either SIP(L19) or
IgG(L19), the biotinylated ED-B domain of Fibronectin, which
includes the epitope recognized by L19, was immobilized on a
streptavidin coated plate (StreptaWell, Roche Applied
Bioscience, Indianapolis, IN, USA). Horseradish peroxidase
conjugated Protein A (GE Healthcare, Buckinghamshire, UK),
diluted according to the manufacturer’s recommendations, was
used as secondary antibody to detect SIPs and IgG1s. In both
cases, the immunoreactivity with the immobilized antigen was
detected using the substrate BluePOD (Roche Diagnostics,
Mannheim, Germany) for peroxidase, and photometric absor-
bance at 405 nm was measured.
Purification and quality control of antibodies
Both SIP(L19) and IgG(L19) could be purified from cell
culture medium by protein A affinity chromatography. After
loading, the column was washed with a buffer containing
100 mM NaCl, 0.1% Tween20, 0.5 mM EDTA. Eluted frac-
tions were then dialyzed against PBS, pH 7.4, at 48C. Batches
Fig. 4. Quality controls of purified SIP(L19) and IgG(L19). (A and B) SDS–PAGE analysis of purified SIP(L19) and IgG(L19) under non-reducing (NR) and
reducing (R) conditions. (C) Size-exclusion chromatography profile of the purified SIP(L19). The retention volume (ml) of the major peak corresponds to the
disulfide-linked homodimer. (D) Size-exclusion chromatography profile of the purified IgG(L19). (E) Mass spectra of SIP(L19). The peak at 38 530 Da
corresponds to the monomeric SIP(L19) as well as to the doubly charged SIP(L19) dimer. The peak at 76 899+41 Da corresponds to the SIP(L19) dimer, in
good agreement with the calculated mass of 77 051 Da for the non-glycosylated product. Furthermore, other charge states and a product of dimer fragmentation
can be observed. (F) 2D-PAGE of SIP(L19) reveals a single spot of unglycosylated protein, using a sample loaded under reducing conditions.
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of the two antibodies were analyzed using SDS–PAGE under
reducing and non-reducing conditions, and by 2D gel electro-
phoresis using the Invitrogen Page system (product codes
ZM0011, ZM0021 and NP0330) following manufacturer
instructions. Moreover, Superdex 200 size exclusion column
(GE Healthcare, Otelfingen, Switzerland) was used to analyze
the gel filtration profiles of the purified antibodies under
native conditions using fast protein liquid chromatography
(FPLC; Amersham Pharmacia).
Mass spectrometric analysis of SIP(L19)
For MALDI-TOF analysis, purified SIP(L19) samples, dialyzed
against PBS, were mixed with matrix (sinapinic acid, 10 mg/ml
in 50% ACN and 0.05% TFA), at a 1:4 dilution and spotted
onto the MALDI target plate. The analysis of samples was per-
formed on freshly tuned AB4800 MALDI-TOF/TOF mass
spectrometer. The calibration of the instrument was performed
using the ProteoMass Protein MALDI-MS Calibration Kit from
Sigma, using the three calibration proteins Apomyoglobin
(16 952 Da), Aldolase (39 212 Da) and Albumin (66 430 Da).
For data analysis, the Data Explorer software version 4.8 from
Applied Biosystems was used.
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